Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416133 | 0.85 | AGBL2 (0.39) | AGBL2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL11872196 | 0.83 | HTT (0.39) | HDAC1HDAC6 | |
| SCHEMBL29009868 | 0.82 | CA1 (0.40) | AGBL2AKR1B1 | |
| SCHEMBL1415209 | 0.81 | AGBL2 (0.42) | AGBL2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL15626646 | 0.78 | MAPT (0.46) | AGBL2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL11269548 | 0.77 | CA1 (0.43) | AGBL2AKR1B1 | |
| SCHEMBL1415207 | 0.77 | PTGS1 (0.40) | AGBL2HDAC1HDAC6MAPTPOLB | |
| SCHEMBL3416138 | 0.77 | AGBL2 (0.42) | AGBL2KDM4EMAPTALDH1A1GAA | |
| SCHEMBL21696348 | 0.74 | HDAC1 (0.30) | HDAC1HDAC6 | |
| SCHEMBL1328731 | 0.74 | AKR1B1 (0.38) | AGBL2KDM4EMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-7932257-B2 | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1915377-A1 | PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007013964-A1 | PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| EP-1268581-B1 | STABLE INITIATOR SYSTEM | JOHNSON & JOHNSON VISION CARE (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1268581-A2 | STABLE INITIATOR SYSTEM | Johnson & Johnson Vision Care, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6414049-B1 | SILICONE, ACYLPHOSPHINE PROMOTER, ACID MIXTURE | JOHNSON & JOHNSON VISION CARE, INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2001070824-A2 | STABLE INITIATOR SYSTEM | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-5925527-A | SCREENING NEW PHARMACEUTICALS | TREGA BIOSCIENCES, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998034113-A1 | COMBINATORIAL LIBRARIES OF BICYCLIC GUANIDINE DERIVATIVES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5622137-A | FOR USE IN TESTING COOKED FOODS | TRANS WORLD SERVICES (US) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | AGBL2 1525/4885HDAC1 1458/4885HDAC6 2900/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | AGBL2 1543/4885HDAC1 1206/4885HDAC6 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.